BFNH
BIOFORCE NANOSCIENCES HOLDINGS, INC.
Next earnings Aug 10, 2026
$1.79
▲ +8.48%$1.79▲ +336.37%
over 1Y
L $0.18H $1.79
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+8.5%
1W+8.5%
1M+135.5%
3M+297.8%
YTD+208.6%
1Y+336.4%
Avoid
Conviction
Horizon
Medium (3–12mo)
Revenue grew 9.0% YoY; but unprofitable (net margin -7268.4%).
Revenue (FY2019) $17.8K · FY2019
BIOFORCE NANOSCIENCES HOLDINGS, INC. shows $17.8K in FY2019 revenue (+9.0% YoY), a -7268.4% net margin, and 208.9% ROE.
Supporting the case: revenue grew 9.0% YoY; high return on equity (208.9%); conservative balance sheet (liabilities/equity -1.00x).
Is BFNH a buy? The one-page verdict, explained →
The options angle
model · matches our verdictBear put spread (caution)~60d expiry
- Long put 2 @ ~1.01 est
- Short put 1.5 @ ~0.65 est
debit $36max +$14max −$36BE 1.64
AVOID means we wouldn't engage at all — if expressing the short side anyway, only with capped risk.
Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | — | — | — | — | — |
| Net income | -$502K | -$486K | -$472K | -$490K | -$1.29M |
| Diluted EPS | — | -$0.02 | -$0.02 | -$0.02 | -$0.04 |
| Net margin | — | — | — | — | — |
10-year statements — income, cash flow, balance sheet & CSV export →
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$60.1M
EV / EBITDA—
EV / Sales3378.4
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-2.2%
FCF yield—
Quality & risk
ROIC (est.)—
Free cash flow—
Total debt—
Net cash$786.00
Altman Z-Score-290342.60 distress
Piotroski F-Score4/8
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+0.0%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — late filing notice (2026-05-13). Worth a closer look.
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-052026-07-01open ↗8-KPeriod ending 2026-04-152026-06-18open ↗10-QPeriod ending 2026-03-312026-05-19open ↗NT 10-QPeriod ending 2026-03-312026-05-13open ↗10-KPeriod ending 2025-12-312026-04-15open ↗NT 10-KPeriod ending 2025-12-312026-03-31open ↗10-QPeriod ending 2025-09-302025-11-19open ↗NT 10-QPeriod ending 2025-09-302025-11-13open ↗10-QPeriod ending 2025-06-302025-08-11open ↗10-QPeriod ending 2025-03-312025-05-13open ↗10-KPeriod ending 2024-12-312025-04-08open ↗NT 10-KPeriod ending 2024-12-312025-03-28open ↗
Frequently asked
- Is BIOFORCE NANOSCIENCES HOLDINGS, INC. (BFNH) a buy?
- BFNH currently carries a Avoid rating with 2/5 conviction, derived from its latest SEC filings. Revenue grew 9.0% YoY; but unprofitable (net margin -7268.4%).
- What is BIOFORCE NANOSCIENCES HOLDINGS, INC.'s quality score?
- BFNH scores 36.07272727272727/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001310488, latest 10-Q filed 2026-05-19) · EODHD · as of 6/22/2026, 11:32:35 PM.
About this recommendation — produced by TENK/calls (tenkcalls.com), Luxembourg · not investment advice
Rule-based analysis, generated automatically from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 22, 2026, 7:32 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.